A NASH player touts positive PhIII data, but true test still lies ahead

After years in which developers faced an essentially unbreakable stonewall for non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease (NAFLD), another biotech is approaching the wall and looking to see whether it can break through — with some new Phase III data.